Abstracts tagged "systemic sclerosis and transforming growth factor"

Abstract Number: 1690 • 2013 ACR/ARHP Annual Meeting
Impaired Vitamin D Receptor Signaling Upregulates Transforming Growth Factor Beta (TGFβ) Signaling In Systemic Sclerosis
Pawel Zerr¹, Stefan Vollath¹, Katrin Palumbo-Zerr¹, Michal Tomcik², Jingang Huang¹, Alfiya Distler¹, Christian Beyer¹, Clara Dees¹, Oliver Distler³, Georg Schett⁴ and Joerg H. W. Distler¹, ¹Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ³Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁴Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Vitamin D receptor (VDR) is a member of the nuclear receptor superfamily. Its ligand, 1,25-(OH)2D, is a metabolically active hormone derived from vitamin D3.…
Abstract Number: 1499 • 2012 ACR/ARHP Annual Meeting
The Soluble Guanylate Cyclase Mediates Its Anti-Fibrotic Effects by Inhibiting TGF-β Signaling
Christian Beyer¹, Sonia C. Schindler², Alfiya Distler³, Clara Dees⁴, Helena Reichert², Hümeyra Akan², Peter Sandner⁵, Oliver Distler⁶, Georg Schett⁷ and Joerg HW Distler³, ¹Department of Internal Medicine 3, Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ³Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Bayer Health Care, Global Drug Discovery – Common Mechanism Research, Bayer Health Care, Global Drug Discovery – Common Mechanism Research, Wuppertal, Germany, ⁶Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁷Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: We have recently demonstrated that stimulation of the soluble guanylate cyclase (sGC) has potent anti-fibrotic activity in different models of fibrosis. sGC stimulation increases…
Abstract Number: L14 • 2012 ACR/ARHP Annual Meeting
Treatment of Diffuse Systemic Sclerosis Patients with Anti-Transforming Growth Factor-Beta, Fresolimumab, Inhibits Transforming Growth Factor-Beta-Regulated Gene Expression in Skin and Is Associated with a Rapid Decline in Skin Score
Robert Lafyatis¹, Sashidhar Nakerakanti², Allison Mathes², Cristina Padilla², Sarah McLaughlin³, Michael R. York², Giuseppina Farina⁴, Romy Christmann¹, Richard P. Polisson⁵ and Robert W. Simms¹, ¹Rheumatology, Boston University School of Medicine, Boston, MA, ²Rheumatology, Boston University Medical Center, Boston, MA, ³Division of Rheumatology, Boston University Medical Center, Boston, MA, ⁴Arthritis center, Boston University, Boston, MA, ⁵Sanofi-Aventis US, Cambridge, MA
Background/Purpose: Transforming growth factor-beta (TGFb) has long been suspected to mediate fibrotic signals in systemic sclerosis (SSc) as it potently stimulates collagen deposition in vitro,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].